In this article, we review current evidence linking immune dysfunction in schizophrenia and
related psychotic disorders focusing particularly on circulating cytokines, oxidative stress …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Background Suicide is a leading cause of death in persons with schizophrenia and other
serious mental illnesses (SMI), however, little is known about the characteristics and …

Anxiety and depression symptoms are frequently experienced by individuals with psychosis,
although prevalence rates have not been reviewed in first-episode psychosis (FEP). The aim …

The heterogeneity in recovery outcomes for individuals with First Episode Psychosis (FEP)
calls for a strong evidence base to inform practice at an individual level. Between 19–89% of …

Purposes To better assess and reduce suicidal risk in first-episode psychosis (FEP), we
aimed to investigate the evolution of suicidal thoughts and behaviors (STBs) and associated …

In schizophrenia spectrum disorders, improvement in symptoms varies between patients
with short and long durations of illness. In this meta-analysis we provided an overview of …

Background Suicide is the main cause of premature death in patients with psychosis.
Therefore, the goal of the present study was to review suicide in adolescents with psychotic …

Current study is focused to enhance the solubility of poorly soluble drug olanzapine (OLZ)
by nanogels drug delivery system, as improved solubility is one of the most important …

Over the past years, there has been a growing interest in the association between lifestyle
psychosocial interventions, severe mental illness, and suicide risk. Patients with severe …